Global Small Cell Lung Cancer Therapeutics Market 2015-2019

Description:

About Small Cell Lung Cancer
Cancer occurs when, after cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in developed and developing countries. Smoking is considered to be the major cause of small cell lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second hand smoking, or on exposure to asbestos, chromium, arsenic, nickel, soot, or radon. The common symptoms associated with lung cancer are chest pain, incurable cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss, shortness of breath, and wheezing. Small cell lung cancer has a poor prognosis and gets diagnosed only at the late stage of disease progression, and hence, has a high mortality rate. There are no therapies available to cure small cell lung cancer in the market.

The analysts forecast the Global Small Cell Lung Cancer Therapeutics market to grow at a CAGR of 3.60 percent over the period 2014-2019.

Covered in this Report
The report, Global Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Small Cell Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
- Americas
- APAC
- EMEA

Key Vendors
- Bristol-Myers Squibb
- GlaxoSmithKline
- Menarini
- Sanofi
- ZIOPHARM Oncology

Other Prominent Vendors
- Alchemia
- Amgen
- Apotex
- BioMarin Pharmaceutical
- CellAct Pharma
- Cerulean Pharma
- Cipla
- Cornerstone Pharmaceuticals
- Curis
- CytRx
- Eli Lilly
- Exelixis
- Fresenius Kabi
- Genentech
- Hikma Pharmaceuticals
- Hospira
- Intas Pharmaceuticals
- Karyopharm Therapeutics
Market Drivers
- High Unmet Need
- For a full, detailed list, view our report

Market Challenges
- High Cost of Treatment
- For a full, detailed list, view our report

Market Trend
- Strategic Alliances
- For a full, detailed list, view our report

Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
05.3 Diagnosis
  05.3.1 Physical Examination
  05.3.2 Laboratory Tests
  05.3.3 Chest X-ray
  05.3.4 Sputum Cytology
  05.3.5 CT Scan
  05.3.6 Biopsy
  05.3.7 Light and Electron Microscopy
  05.3.8 Immunohistochemistry
  05.4 Rate of Incidence and Prevalence
  05.5 Staging
  05.6 Management
  05.7 Economic Burden

06. Introduction

07. Market Landscape
  07.1 Market Overview
  07.2 Market Size and Forecast
  07.3 Top Predictions
  07.4 Five Forces Analysis
  08 Pipeline Analysis
  08.1 Key Information on the Pipeline Candidates
  08.1.1 Palifosfamide (ZIO-201)
  08.1.2 Ipilimumab+Etoposide+Cisplatin/Carboplatin
  08.1.3 Ipilimumab
  08.1.4 Enoxaparin Sodium
  08.1.5 BAY1000394 (Roniciclib)
  08.1.6 Nivolumab (ONO-4538/ BMS-936558)
  08.1.7 BMS-986012
  08.1.8 LY2940680
  08.1.9 Sabarubicin (MEN 10755)
  08.1.10 CAP7.1
  08.1.11 SC16LD6.5
  08.1.12 BIW-8962
  08.1.13 AMG 479 (Ganitumab)
  08.1.14 LY2510924
  08.1.15 Trisenox
  08.1.16 MGN1703
  08.1.17 Tarextumab (OMP-59R5)
  08.1.18 BMN 673 (Talazoparib Tosylate)
  08.1.19 NGR-hTNF
  08.1.20 CPI-613
  08.1.21 Alisertib (MLN8237)
  08.1.22 Vismodegib (GDC-0449, Erivedge)
  08.1.23 Cabozantinib (XL184 or Cometriq)
  08.1.24 Selinexor (KPT-330)
  08.1.25 ADI-PEG 20 (Pegarginimase)
  08.1.26 Etrinotecan Pegol (NKTR-102)
  08.1.27 CRLX101 (IT-101 or Cyclodextrin-based Polymer-camptothecin IT-101)
  08.1.28 NTX-010
  08.1.29 Aldoxorubicin
  08.1.30 HA-Irinotecan
  08.1.31 Carfilzomib
  08.1.32 Small Cell Lung Cancer Vaccine
  08.1.33 GSK2879552
  08.1.34 NV-344 (ME-344)
  08.1.35 BMS-833923 (XL139)
  08.1.36 PM01183 (Lurbinectedin)
  08.1.37 LDE225 (Erismodegib or Sonidegib)
  08.1.38 Belinostat
  08.2 Timeline for Major Products under Development
  08.2.1 Palifosfamide (ZIO-201)
  08.2.2 Sabarubicin (MEN 10755)

09. Market Segmentation by Therapeutic Class of Drugs
09.1 Alkylating Agents
09.2 Antimetabolites
09.3 Microtubule Inhibitors
09.4 Cytotoxic Antibiotics
09.5 Topoisomerase Inhibitors
09.6 Others
10 Market Segmentation by Route of Administration
  10.1 Oral
  10.2 Parenteral
11 Market Segmentation by Dosage Form
  11.1 Solid
  11.2 Liquid
12 Geographical Segmentation
  12.1 Small Cell Lung Cancer Market in Americas
    12.1.1 Market Size and Forecast
  12.2 Small Cell Lung Cancer Market in EMEA Region
    12.2.1 Market Size and Forecast
  12.3 Small Cell Lung Cancer Market in APAC Region
    12.3.1 Market Size and Forecast
13 Buying Criteria
14 Market Growth Drivers
15 Drivers and their Impact
16 Market Challenges
17 Impact of Drivers and Challenges
18 Market Trends
19 Trends and their Impact
20 Vendor Landscape
  20.1 Competitive Scenario
    20.1.1 Key News
    20.1.2 Mergers and Acquisitions
    20.2 Market Share Analysis 2014
      20.2.1 Bristol-Myers Squibb
      20.2.2 GlaxoSmithKline
      20.2.3 Menarini
      20.2.4 Sanofi
      20.2.5 ZIOPHARM Oncology
    20.3 Other Prominent Vendors
  21 Key Vendor Analysis
    21.1 Bristol-Myers Squibb
      21.1.1 Key Facts
      21.1.2 Business Overview
      21.1.3 Business Segmentation
      21.1.4 Revenue by Geography
      21.1.5 Business Strategy
      21.1.6 Key Information
    21.2 GlaxoSmithKline
      21.2.1 Key Facts
      21.2.2 Business Overview
      21.2.3 Business Segmentation
      21.2.4 Business Segmentation by Revenue 2012 and 2013
      21.2.5 Sales by Geography
      21.2.6 Pipeline Products
      21.2.7 Business Strategy
      21.2.8 Key Information
      21.2.9 SWOT Analysis
    21.3 Menarini
      21.3.1 Key Facts
      21.3.2 Business Overview
      21.3.3 Key Pipeline Products
      21.3.4 Recent Developments
      21.3.5 SWOT Analysis
    21.4 Sanofi
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis
21.5 ZIOPHARM Oncology
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Recent Developments
21.5.4 SWOT Analysis
22 Other Reports in this Series

List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Classification of Lung Cancer
Exhibit 3: Techniques for Diagnosing Small Cell Lung Cancer
Exhibit 4: Incidence of Lung Cancer in WHO Regions
Exhibit 5: Staging of Small Cell Lung Cancer
Exhibit 6: Small Cell Lung Cancer by Stage
Exhibit 7: Five-year Survival Rate of Small Cell Lung Cancer Patients
Exhibit 8: Stepwise Diagrammatic Representation of Management of Small Cell Lung Cancer (According to ESMO Guidelines)
Exhibit 10: Top Predictions in Global Small Cell Lung Cancer Therapeutics Market
Exhibit 11: Pipeline Portfolio of Small Cell Lung Cancer Drugs
Exhibit 12: Timeline of Palifosfamide (ZIO-201)
Exhibit 13: Timeline of Sabarubicin (MEN 10755)
Exhibit 14: Global Small Cell Lung Cancer Therapeutics Market by Therapeutic Class of Drugs
Exhibit 15: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Route of Administration
Exhibit 16: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Route of Administration 2014
Exhibit 17: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Dosage Forms
Exhibit 18: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Dosage Forms 2014
Exhibit 19: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Geography 2014
Exhibit 20: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Geography 2019
Exhibit 23: Small Cell Lung Cancer Therapeutics Market in APAC Region 2014-2019 (US$ million)
Exhibit 24: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 25: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 26: GlaxoSmithKline: Business Segmentation 2013
Exhibit 27: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 28: GlaxoSmithKline: Sales by Geography 2013
Exhibit 29: GlaxoSmithKline: Pipeline Products 2013
Exhibit 30: Menarini: Key Pipeline Products
Exhibit 31: Sanofi SA: Business Segmentation
Exhibit 32: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 33: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 34: Sanofi SA: Sales Revenue by Geographical Segmentation 2013

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3138732/
Order by Fax - using the form below
Order by Post - print the order form below and send to Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Global Small Cell Lung Cancer Therapeutics Market 2015-2019
- **Web Address:** http://www.researchandmarkets.com/reports/3138732/
- **Office Code:** SCBRONQN

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td></td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 4500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- **Title:** (Mr, Mrs, Dr, Miss, Ms, Prof)
- **First Name:** __________________________
- **Last Name:** __________________________
- **Email Address:** *
- **Job Title:** __________________________
- **Organisation:** ________________________
- **Address:** ____________________________
- **City:** _____________________________
- **Postal / Zip Code:** __________________
- **Country:** __________________________
- **Phone Number:** ______________________
- **Fax Number:** ________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number: 833 130 83
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World